Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript
Collegium Pharmaceutical (COLL) reported Q2 2026 results on an earnings call. Total net product revenue was $199.9M (+6% YoY). Jornay PM revenue rose to $46.1M (+41%) with 30,000+ prescribers. Azstarys revenue was $12.9M post-May acquisition. 2026 guidance: product revenue $825M-$855M; adjusted EBITDA $445M-$470M; adjusted EPS $1.92. Risks cited include authorized-generic pricing impacts.
How this was made
The 30-second read
Why it matters
Traders should focus on the updated FY2026 guidance ranges and management’s stated drivers: lower Nucynta franchise revenue from authorized generic net pricing, partially offset by higher Azstarys revenue outlook and continued Jornay PM share gains.
Market read
The article contains a full set of quarterly metrics plus explicit FY2026 guidance revisions, making it actionable for re-pricing expectations around ADHD growth versus pain pricing risk.
What to watch
Authorized generic settlement terms and the potential Belbuca generic launch timing (Jan 2027) could create a forward-looking overhang not fully captured by the current quarter’s numbers.
Background
This is Collegium Pharmaceutical’s Q2 2026 earnings call transcript, covering ADHD franchise performance, the May Azstarys acquisition integration, and pain portfolio pricing headwinds.
Ticker impact
Collegium reported Q2 results and updated 2026 guidance, including Azstarys revenue range and lower Nucynta franchise outlook tied to authorized generic pricing.
Likely choppy trading around guidance interpretation, with upside bias if investors focus on Jornay PM share gains and Azstarys ramp, offset by concerns over Nucynta pricing pressure.
The article provides multiple hard guidance datapoints (revenue, adjusted EBITDA, EPS) plus explicit management rationale for the Nucynta franchise reset from authorized generic dynamics, which are direct drivers for earnings expectations.
Market effects
Highlights ongoing competitive pricing pressure in branded opioid and authorized-generic frameworks, while ADHD CNS brands can still gain share via prescriber expansion.
Limited; company-specific US commercial dynamics dominate.
Limited; primarily US formulary and prescriber adoption metrics.
Counterpoint
The Azstarys guidance increase may be partially offset by continued margin pressure from pain franchise authorized generic dynamics, so the net earnings quality could be weaker than revenue growth suggests.
Key entities
- companyCollegium Pharmaceutical, Inc.
Subject of the earnings call, reporting Q2 results and updating 2026 guidance across ADHD and pain products.
- productAzstarys
ADHD medicine acquired in May, with guidance increased to $65M-$75M for 2026.
- product_franchiseNucynta franchise
Pain portfolio segment facing lower net pricing for authorized generics, driving guidance changes.
- productBelbuca
Pain medicine where management referenced settlement-related generic launch risk in Jan 2027.
